Panel of FDA advisers says the medication remains safe and effective for high-risk patients
Viral, Symptom Rebound Common After COVID-19 Infection
Incidence of symptom rebound was higher in the nirmatrelvir plus ritonavir treatment group
Feds Will Start Limiting Telehealth Prescriptions for Painkillers, ADHD Drugs
Patients will be required to see a doctor in person to get a first prescription for opioids, ADHD drugs
Pegylated Interferon Lambda Effective in Preventing Severe COVID-19
Incidence of hospitalization or emergency department visit lower for those receiving interferon versus placebo
No Increase Seen in OD Deaths Involving Buprenorphine During COVID-19
Proportion of overdose deaths did not increase in association with actions taken to ease access to buprenorphine
Fluvoxamine Does Not Improve Time to Sustained Recovery in Mild COVID-19
No difference seen for fluvoxamine, placebo in composite outcome of hospitalization, urgent care visit, emergency department visit, death
VV116 Noninferior to Nirmatrelvir-Ritonavir for COVID-19
Noninferiority established with respect to time to sustained clinical recovery for adults at high risk for progression
Molnupiravir Does Not Reduce COVID-19-Related Hospitalization, Death
No reduction in COVID-19-associated hospitalizations or deaths seen among high-risk, vaccinated adults
Nirmatrelvir Plus Ritonavir Reduces Risks for COVID-19 in Seniors
Reduced risks for hospitalization and death observed for mainly vaccinated outpatients aged 50 years or older with COVID-19
Fewer Buprenorphine Initiation Episodes Seen During Pandemic
Number of active buprenorphine episodes comparable to expected number, with fewer initiations and fewer ending of episodes